Back to search results

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

IsraelRecruitingPHASE1, PHASE2

Conditions

Ovarian Cancer Recurrent

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019), New Haven, Connecticut, United States

    Study coordinator · 203-785-2404

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0009), Louisville, Kentucky, United States

    Study coordinator · 502-562-3429

  • Dana-Farber Cancer Institute ( Site 0015), Boston, Massachusetts, United States

    Study coordinator · 877-338-7425

  • Memorial Sloan Kettering Cancer Center ( Site 0003), New York, New York, United States

    Study coordinator · 212-639-2000

  • OU Health University of Oklahoma Medical Center ( Site 7000), Oklahoma City, Oklahoma, United States

    Study coordinator · 405-271-1112

  • Texas Oncology - DFW ( Site 8000), Fort Worth, Texas, United States

    Study coordinator · 615-329-7430

  • Houston Methodist Hospital ( Site 0010), Houston, Texas, United States

  • START Mountain Region ( Site 0008), West Valley City, Utah, United States

    Study coordinator · 801-907-4750

  • University of Virginia Health System ( Site 0011), Charlottesville, Virginia, United States

    Study coordinator · 434-924-9333

  • McGill University Health Centre ( Site 0100), Montreal, Quebec, Canada

    Study coordinator · 514-934-1934x31975

  • Rambam Health Care Campus ( Site 0202), Haifa, Israel

    Study coordinator · 972-4-7776234

  • Shaare Zedek Medical Center ( Site 0201), Jerusalem, Israel

    Study coordinator · +972-(0)2-6555424

  • Rabin Medical Center ( Site 0203), Petah Tikva, Israel

    Study coordinator · +97239378076

  • Sheba Medical Center ( Site 0200), Ramat Gan, Israel

    Study coordinator · 972-3-5304498

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0302), L'Hospitalet de Llobregat, Barcelona, Spain

    Study coordinator · +34932607744

  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307), Majadhonda, Madrid, Spain

    Study coordinator · +34 911917358

  • Clinica Universidad de Navarra ( Site 0301), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · +349135319207513

  • Hospital General Universitario de Valencia ( Site 0305), Valencia, Valenciana, Comunitat, Spain

    Study coordinator · +34 963187527

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300), Barcelona, Spain

    Study coordinator · +349325434528607

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303), Madrid, Spain

    Study coordinator · 34915504800 x2805

  • Hospital Universitario 12 de Octubre ( Site 0304), Madrid, Spain

    Study coordinator · +34913908626

  • Hospital Universitario Virgen de la Victoria ( Site 0306), Málaga, Spain

    Study coordinator · +34951032508

  • University Hospitals Sussex NHS Foundation Trust ( Site 0404), Brighton, East Sussex, United Kingdom

    Study coordinator · +44 01273 696 955

  • Royal Marsden Hospital ( Site 0402), Fulham, England, United Kingdom

    Study coordinator · +442078118084

  • The Royal Marsden NHS Foundation Trust. ( Site 0403), Sutton, England, United Kingdom

    Study coordinator · +442078118084

  • Barts Health NHS Trust ( Site 0401), London, London, City of, United Kingdom

    Study coordinator · 020 7377 7000

  • Guy s & St Thomas NHS Foundation Trust ( Site 0400), London, London, City of, United Kingdom

    Study coordinator · +44 020 7188 7188

  • The Christie NHS Foundation Trust ( Site 0405), Manchester, United Kingdom

    Study coordinator · +441619187689
Study leads

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov(opens in a new tab)